INT69761

From wiki-pain
Revision as of 00:14, 22 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.67
First Reported 1997
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 7
Disease Relevance 6.17
Pain Relevance 0.53

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Jag2)
Anatomy Link Frequency
fibroblasts 3
bone marrow 1
Jag2 (Mus musculus)
Pain Link Frequency Relevance Heat
Pain threshold 1 99.98 Very High Very High Very High
narcan 2 97.04 Very High Very High Very High
agonist 18 96.24 Very High Very High Very High
Antinociceptive 3 92.96 High High
Inflammation 18 89.76 High High
Nicotine 1 86.48 High High
antinociception 1 75.00 Quite High
cytokine 11 46.48 Quite Low
chemokine 2 45.88 Quite Low
Pain 22 36.52 Quite Low
Disease Link Frequency Relevance Heat
Systemic Mastocytosis 78 100.00 Very High Very High Very High
Pain 15 99.98 Very High Very High Very High
Cutaneous Mastocytosis 48 99.96 Very High Very High Very High
Apoptosis 189 98.48 Very High Very High Very High
Urticaria Pigmentosa 2 97.20 Very High Very High Very High
Exanthema 2 96.24 Very High Very High Very High
Stress 57 92.56 High High
INFLAMMATION 21 89.76 High High
Mycobacterial Infection 124 86.72 High High
Hypotension 4 75.84 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The increase in the pain threshold produced by SM 32 was prevented by dicyclomine, pirenzepine and hemicholinium-3 but not by naloxone and CGP 35348.
Gene_expression (produced) of SM 32 associated with pain threshold and narcan
1) Confidence 0.67 Published 1997 Journal Pharmacol. Res. Section Abstract Doc Link 9175584 Disease Relevance 0.10 Pain Relevance 0.39
In adults, however, CM frequently progresses to SM.
Gene_expression (progresses) of SM associated with cutaneous mastocytosis and systemic mastocytosis
2) Confidence 0.19 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2386235 Disease Relevance 2.06 Pain Relevance 0
In contrast to CM, SM has a peak onset in adults, tends to be more aggressive, and can involve the skin as well as internal organs and bone marrow.
Gene_expression (aggressive) of SM in bone marrow associated with cutaneous mastocytosis and systemic mastocytosis
3) Confidence 0.19 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2386235 Disease Relevance 2.12 Pain Relevance 0
was apparently independent of nSMase2 and SM hydrolysis in murine fibroblasts, since similar apoptosis was observed in nSMase2-deficient cells, and since rescuing the activity of the nSMase2 did not alter the apoptosis induced by TNF?
Gene_expression (hydrolysis) of SM in fibroblasts associated with apoptosis
4) Confidence 0.13 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2843740 Disease Relevance 0.97 Pain Relevance 0.04
In contrast, in fro/fro fibroblasts, SM hydrolysis (Figure 2A,B), basal nSMase activity (Figure 2C), and nSMase activation triggered by the two agonists (Figure 2D) were deficient.
Gene_expression (hydrolysis) of SM in fibroblasts associated with agonist
5) Confidence 0.11 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2843740 Disease Relevance 0.32 Pain Relevance 0.05
and oxLDLs triggered both SM hydrolysis (Figure 2A,B) and nSMase activation in wt fibroblasts (Figure 2D).
Gene_expression (hydrolysis) of SM in fibroblasts
6) Confidence 0.11 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2843740 Disease Relevance 0.40 Pain Relevance 0.04
The doses of OPC-67683, RFP, INH, EB, SM, and PZA that could produce a CFU reduction of at least 95% in this experimental mouse model were 0.625, 3.5, 5, >160, 40, and 160 mg/kg, respectively.


Gene_expression (produce) of SM
7) Confidence 0.03 Published 2006 Journal PLoS Medicine Section Body Doc Link PMC1664607 Disease Relevance 0.21 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox